CN111225669A - 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i - Google Patents

作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i Download PDF

Info

Publication number
CN111225669A
CN111225669A CN201880067323.9A CN201880067323A CN111225669A CN 111225669 A CN111225669 A CN 111225669A CN 201880067323 A CN201880067323 A CN 201880067323A CN 111225669 A CN111225669 A CN 111225669A
Authority
CN
China
Prior art keywords
compound
reaction
azaspiro
formula
chloropyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880067323.9A
Other languages
English (en)
Other versions
CN111225669B (zh
Inventor
吴予川
陈曦
黄少强
胡永韩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Suzhou Sinoway Pharmaceutical Technology Co ltd
Original Assignee
Suzhou Sinovent Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suzhou Sinovent Pharmaceuticals Co Ltd filed Critical Suzhou Sinovent Pharmaceuticals Co Ltd
Publication of CN111225669A publication Critical patent/CN111225669A/zh
Application granted granted Critical
Publication of CN111225669B publication Critical patent/CN111225669B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一种如式(I)所示的新型5‑氨基吡唑甲酰胺化合物的晶型。此外，本发明还公开了上述化合物的晶型的制备方法以及包含上述化合物晶型的药物组合物及其用途。

Description

PCT国内申请，说明书已公开。

Claims (8)

  1. PCT国内申请，权利要求书已公开。
CN201880067323.9A 2017-11-10 2018-11-08 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i Active CN111225669B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201711104892X 2017-11-10
CN201711104892 2017-11-10
PCT/CN2018/114666 WO2019091440A1 (zh) 2017-11-10 2018-11-08 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i

Publications (2)

Publication Number Publication Date
CN111225669A true CN111225669A (zh) 2020-06-02
CN111225669B CN111225669B (zh) 2020-12-29

Family

ID=66437594

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880067323.9A Active CN111225669B (zh) 2017-11-10 2018-11-08 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i

Country Status (5)

Country Link
US (1) US11180475B2 (zh)
EP (1) EP3708165B1 (zh)
CN (1) CN111225669B (zh)
AU (1) AU2018364183B2 (zh)
WO (1) WO2019091440A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014068527A1 (en) * 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
WO2017198050A1 (zh) * 2016-05-16 2017-11-23 浙江予川医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0121440D0 (en) 2001-09-04 2001-10-24 Pfizer Ltd Assay
CN103848810A (zh) 2012-11-30 2014-06-11 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN105085474B (zh) 2014-05-07 2018-05-18 北京赛林泰医药技术有限公司 鲁顿酪氨酸激酶抑制剂
CN111153906B (zh) * 2016-05-16 2020-09-11 苏州信诺维医药科技有限公司 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
WO2019091441A1 (zh) 2017-11-10 2019-05-16 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014068527A1 (en) * 2012-11-02 2014-05-08 Pfizer Inc. Bruton's tyrosine kinase inhibitors
WO2017198050A1 (zh) * 2016-05-16 2017-11-23 浙江予川医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物

Also Published As

Publication number Publication date
CN111225669B (zh) 2020-12-29
US20200361902A1 (en) 2020-11-19
EP3708165B1 (en) 2023-01-18
EP3708165A1 (en) 2020-09-16
EP3708165A4 (en) 2021-06-09
WO2019091440A1 (zh) 2019-05-16
US11180475B2 (en) 2021-11-23
AU2018364183B2 (en) 2020-10-15
AU2018364183A1 (en) 2020-05-28

Similar Documents

Publication Publication Date Title
CN107382973B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺衍生物及其制备方法和药物组合物
KR102387316B1 (ko) Mdm2 단백질 분해제
CN107922431B (zh) Hpk1抑制剂及其使用方法
KR102085121B1 (ko) 이미다조[1,2-b]피리다진계 화합물, 그를 포함하는 조성물 및 그의 용도
JP2011513468A (ja) 新規なｎ−置換テトラヒドロイソキノリン／イソインドリンヒドロキサム酸化合物
KR20090074762A (ko) 특정 치환된 아미드, 그의 제조 방법, 및 그의 사용 방법
MX2007000265A (es) Compuestos utiles para inhibir chk1.
CN109810041A (zh) 卤代烯丙基胺类ssao/vap-1抑制剂及其应用
CN111153906B (zh) 作为btk抑制剂的吡唑并嘧啶衍生物及其制备方法和药物组合物
KR20140095513A (ko) 이미다조피리다진 화합물
TWI707855B (zh) 咪唑并嗒類化合物及其用途
EP2334683B1 (en) Saturated bicyclic heterocyclic derivatives as smo antagonists
CN111225912B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺化合物及其制备方法
WO2014090715A1 (en) Thiazole derivatives as inhibitors of bruton's tyrosine kinase
WO2020231739A2 (en) Compounds and methods for treating cancer
CN111212644B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
TW202106685A (zh) 抗b型肝炎病毒(hbv)之新穎苯基及吡啶基脲活性劑
CN111225669B (zh) 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的晶型i
EP1433789A1 (en) Pyrrolopyrazines and their use as selective apoptosis inducers

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: 215127 building 22, area B, phase II, bio Industrial Park, 218 Sangtian street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee after: Suzhou Sinoway Pharmaceutical Technology Co.,Ltd.

Address before: 215127 building 22, area B, phase II, bio Industrial Park, 218 Sangtian street, Suzhou Industrial Park, Suzhou City, Jiangsu Province

Patentee before: Suzhou Sinovent Pharmaceuticals Co.,Ltd.